Paziente con patologie e/o condizioni di rischio diverse dal DMT2
1 2 3

Seleziona una delle seguenti opzioni:

Paziente con ipercolesterolemia familiare1
Paziente con ipercolesterolemia familiare e patologia aterosclerotica o altro fattore di rischio maggiore5
Paziente con patologia aterosclerotica accertata1
Paziente con malattia renale cronica moderata1
  • eGFR 30-44 mL/min/1,73 m2 e ACR <30
  • eGFR 45-59 mL/min/1,73 m2 e ACR 30-300
  • eGFR ≥ 60 mL/min/1,73 m2 e ACR >300
Paziente con malattia renale cronica severa1
  • eGFR<30 mL/min/1,73 m2
  • eGFR 30-44 mL/min/1,73 m2 e ACR >30
  • ACR: rapporto albuminuria/creatininuria
  • ASCVD: Malattia cardiovascolare aterosclerotica
  • CV: cardiovascolare
  • DMT2: diabete mellito di tipo 2
  • eGFR: tasso di filtrazione glomerulare stimato
  • ESC: European Society of Cardiology (Società Europea di Cardiologia)
  • GLP1 RA: agonisti recettoriali del GLP-1
  • HbA1c: emoglobina glicata
  • HDL: Lipoproteine ad alta densità
  • LDL: Lipoproteine a bassa densità
  • PAS: pressione arteriosa sistolica
  • SGLT2: co-trasportatore sodio-glucosio di tipo 2
  • TOD: Danno ad organi bersaglio
  1. Visseren FLJ, et al., ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337
  2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454
  3. https://www.epicentro.iss.it/passi/dati/alcol?tab-container-1=tab1#indicatori. Ultimo accesso il 26/03/2025
  4. Marx N, et al., ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140
  5. Mach F, et al., ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188
  6. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 July 21; 44(28):2544–2556
  7. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. Supplementary Material
  8. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 July 21; 44(28):2544–2556, Appendix 1.
  • ACR: rapporto albuminuria/creatininuria
  • ASCVD: Malattia cardiovascolare aterosclerotica
  • CV: cardiovascolare
  • DMT2: diabete mellito di tipo 2
  • eGFR: tasso di filtrazione glomerulare stimato
  • ESC: European Society of Cardiology (Società Europea di Cardiologia)
  • GLP1 RA: agonisti recettoriali del GLP-1
  • HbA1c: emoglobina glicata
  • HDL: Lipoproteine ad alta densità
  • LDL: Lipoproteine a bassa densità
  • PAS: pressione arteriosa sistolica
  • SGLT2: co-trasportatore sodio-glucosio di tipo 2
  • TOD: Danno ad organi bersaglio
  1. Visseren FLJ, et al., ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337
  2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454
  3. https://www.epicentro.iss.it/passi/dati/alcol?tab-container-1=tab1#indicatori. Ultimo accesso il 26/03/2025
  4. Marx N, et al., ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140
  5. Mach F, et al., ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188
  6. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 July 21; 44(28):2544–2556
  7. SCORE2 working group and ESC Cardiovascular risk collaboration , SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe, European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454,Supplement.
  8. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 July 21; 44(28):2544–2556, Appendix 1.
Menarini Copyright © 2025 Menarini | Privacy Policy | Cookie Policy | Menarini
Copyright © 2025 Menarini
Privacy Policy | Cookie Policy |